Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viatris IncVTRS · Entity 3277 | Director · Executive Chairman | March 02, 2023 | March 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viatris Inc
Report date March 02, 2023 · Filed March 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,174,515 |
Ending reported balance
After 2023-03-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2023-03-02 · Exercise / conversion · Acquired 100,770 · Balance 1,162,429 Row 2 · 2023-03-02 · Tax withholding · Disposed 52,851 · Balance 1,109,578 F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 2, 2021. Row 3 · 2023-03-02 · Exercise / conversion · Acquired 7,969 · Balance 1,117,547 F2: Fractional shares have been rounded up in connection with the settlement described in footnote 9 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Row 4 · 2023-03-02 · Tax withholding · Disposed 4,124 · Balance 1,113,423 F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 2, 2021. Row 5 · 2023-03-04 · Exercise / conversion · Acquired 123,529 · Balance 1,236,952 Row 6 · 2023-03-04 · Tax withholding · Disposed 64,557 · Balance 1,172,395 F4: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 4, 2022. Row 7 · 2023-03-04 · Exercise / conversion · Acquired 4,441 · Balance 1,176,836 F5: Fractional shares have been rounded up in connection with the settlement described in footnote 13 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Row 8 · 2023-03-04 · Tax withholding · Disposed 2,321 · Balance 1,174,515 F6: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the DEUs that accrued with respect to the RSUs previously granted on March 4, 2022. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 100,770 |
Reported balance
After 2023-03-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-02 · Exercise / conversion · Disposed 100,770 · Balance 100,770 F7: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 100,770 of the RSUs granted on March 2, 2021 vested on each of March 2, 2022 and March 2, 2023 and 100,770 will vest on March 2, 2024. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 367,925 |
Reported balance
After 2023-03-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-03-03 · Grant · Acquired 367,925 · Balance 367,925 F10: Each RSU represents the right to receive one share of common stock of Viatris. 122,642 of the RSUs granted on March 3, 2023 will vest on March 3, 2024, 122,641 will vest on March 3, 2025 and 122,642 will vest on March 3, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 247,060 |
Reported balance
After 2023-03-04 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-03-04 · Exercise / conversion · Disposed 123,529 · Balance 247,060 F11: Each RSU represents the right to receive one share of common stock of Viatris. 123,529 of the RSUs granted on March 4, 2022 vested on March 4, 2023 and 123,530 will vest on each of March 4, 2024 and March 4, 2025. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 7,969 |
Reported balance
After 2023-03-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-03-02 · Exercise / conversion · Disposed 7,968.3174 · Balance 7,969 F8: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount includes DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. F9: Represents DEUs that accrued with respect to the RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs. |
| Dividend Equivalent UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,881 |
Reported balance
After 2023-03-04 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-03-04 · Exercise / conversion · Disposed 4,440.4284 · Balance 8,881 F12: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount represents DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11. F13: Represents DEUs that accrued with respect to the RSUs previously granted on March 4, 2022 and vest on the same schedule as the underlying RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the restricted stock units (RSUs) granted on March 2, 2021.
F2: Fractional shares have been rounded up in connection with the settlement described in footnote 9 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F3: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on March 2, 2021.
F4: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the RSUs granted on March 4, 2022.
F5: Fractional shares have been rounded up in connection with the settlement described in footnote 13 pursuant to the terms of the RSU award agreement under the Viatris Inc. 2020 Stock Incentive Plan.
F6: Represents withholding of shares of common stock for the tax liability associated with the vesting and settlement of a portion of the DEUs that accrued with respect to the RSUs previously granted on March 4, 2022.
F7: Each RSU represents the right to receive one share of common stock of Viatris Inc. (Viatris). 100,770 of the RSUs granted on March 2, 2021 vested on each of March 2, 2022 and March 2, 2023 and 100,770 will vest on March 2, 2024.
F8: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount includes DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11.
F9: Represents DEUs that accrued with respect to the RSUs previously granted on March 2, 2021 and vest on the same schedule as the underlying RSUs.
F10: Each RSU represents the right to receive one share of common stock of Viatris. 122,642 of the RSUs granted on March 3, 2023 will vest on March 3, 2024, 122,641 will vest on March 3, 2025 and 122,642 will vest on March 3, 2026.
F11: Each RSU represents the right to receive one share of common stock of Viatris. 123,529 of the RSUs granted on March 4, 2022 vested on March 4, 2023 and 123,530 will vest on each of March 4, 2024 and March 4, 2025.
F12: On May 6, 2022, Viatris filed a registration statement on Form S-3 with respect to its Dividend Reinvestment and Share Purchase Plan; amount represents DEUs that subsequently accrued with respect to such RSUs in June 2022, September 2022 and December 2022 in transactions exempt from Section 16 under Rule 16a-11.
F13: Represents DEUs that accrued with respect to the RSUs previously granted on March 4, 2022 and vest on the same schedule as the underlying RSUs.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mylan II B.V.
Report date November 16, 2020 · Filed November 18, 2020
Section 16 reporting ended · disclosed 2020-11-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 1,383,587 · Balance 0 F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). F2: 436,393 ordinary shares were returned to the reporting person's direct beneficial ownership on August 16, 2019 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 700,000 ordinary shares on August 1, 2017. F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $22.66 · Expires 2021-03-02 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 4,413 · Balance 0 F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F5: These options vested on March 2, 2014. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $23.44 · Expires 2022-02-22 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 4,266 · Balance 0 F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F6: These options vested on February 22, 2015. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $30.90 · Expires 2023-03-06 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 3,236 · Balance 0 F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F7: These options vested on March 6, 2016. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $55.84 · Expires 2024-03-05 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 58,952 · Balance 0 F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F8: These options vested on March 5, 2017. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $50.66 · Expires 2025-11-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 63,235 · Balance 0 F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F9: These options vested on March 4, 2018. |
| Employee Stock Option - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $46.27 · Expires 2026-02-17 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 82,776 · Balance 0 F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. F10: These options vested on February 17, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 250,000 · Balance 0 F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. F12: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on June 24, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).
F2: 436,393 ordinary shares were returned to the reporting person's direct beneficial ownership on August 16, 2019 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 700,000 ordinary shares on August 1, 2017.
F3: Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.
F4: Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination.
F5: These options vested on March 2, 2014.
F6: These options vested on February 22, 2015.
F7: These options vested on March 6, 2016.
F8: These options vested on March 5, 2017.
F9: These options vested on March 4, 2018.
F10: These options vested on February 17, 2019.
F11: Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination.
F12: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on June 24, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2019 Filed Jun 25, 2019 20:04 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 750,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-018181 · doc4.xml · derivative · entry 4 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Ordinary Shares · 750,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. (subject to the cash-settlement of a portion thereof as described above). 750,000 of the RSUs granted on June 24, 2016 vested on June 24, 2019, and 250,000 will vest on June 24, 2021. F2 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan N.V. (subject to the cash-settlement of a portion thereof as described above). 750,000 of the RSUs granted on June 24, 2016 vested on June 24, 2019, and 250,000 will vest on June 24, 2021. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 20:04 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerOrdinary Shares | 412,500 | $17.96 | $7,408,500.00 |
DisclosureSEC source: 0000899243-19-018181 · doc4.xml · nonDerivative · entry 2 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,335 F1 · shares: A portion of the restricted stock units (RSUs) vesting on June 24, 2019 was settled in cash, based on the closing price of an ordinary share of Mylan N.V. on June 24, 2019, in order to facilitate the satisfaction of the tax liability associated with the vesting and settlement of such RSUs. Read SEC document |
| June 24, 2019 Filed Jun 25, 2019 20:04 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 750,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-018181 · doc4.xml · nonDerivative · entry 1 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,309,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:18 UTC | Mylan II B.V. MYL · Entity 16217 | Disposition to issuerOrdinary Shares | 270,051 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006214 · doc4.xml · nonDerivative · entry 1 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,835 F1 · shares: Represents forfeiture of unvested restricted ordinary shares received under the One-Time Special Performance-Based Five-Year Realizable Value Incentive Program as a result of the applicable performance conditions not having been met. F2 · balance_after: 271,115 ordinary shares were returned to the reporting person's direct beneficial ownership on May 1, 2018 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 1,000,000 ordinary shares on April 26, 2016. F3 · balance_after: 263,607 ordinary shares were returned to the reporting person's direct beneficial ownership on August 20, 2018 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 700,000 ordinary shares on August 1, 2017. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 20:10 UTC | Mylan II B.V. MYL · Entity 16217 | SaleOrdinary Shares | 50,000 | $43.41 | $2,170,685.00 |
DisclosureSEC source: 0000899243-18-006530 · doc4.xml · nonDerivative · entry 3 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Grantor Retained Annuity Trust Disclosed balance after: 271,115 F3 · price: Represents the weighted average price of the reporting person's disposition of 50,000 shares in transactions ranging from $43.40 to $43.51. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ordinary shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 20:10 UTC | Mylan II B.V. MYL · Entity 16217 | SaleOrdinary Shares | 150,000 | $40.10 | $6,014,625.00 |
DisclosureSEC source: 0000899243-18-006530 · doc4.xml · nonDerivative · entry 2 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Grantor Retained Annuity Trust Disclosed balance after: 321,115 F2 · price: Represents the weighted average price of the reporting person's disposition of 150,000 shares in transactions ranging from $40.00 to $40.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ordinary shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: 528,885 ordinary shares were returned to the reporting person's direct beneficial ownership on May 23-24, 2017 in the form of a scheduled annuity payment under the terms of the grantor retained annuity trust to which the reporting person initially contributed 1,000,000 ordinary shares on April 26, 2016. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 96,283 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · derivative · entry 10 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 96,283 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were granted on February 17, 2016. The PRSUs vested on June 24, 2016 and were settled on December 28, 2016. F6 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were granted on February 17, 2016. The PRSUs vested on June 24, 2016 and were settled on December 28, 2016. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 71,951 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · derivative · entry 9 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 71,951 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were granted on November 17, 2015. The PRSUs vested on June 24, 2016 and were settled on December 28, 2016. F5 · derivative.expiration_date: Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were granted on November 17, 2015. The PRSUs vested on June 24, 2016 and were settled on December 28, 2016. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionRestricted Stock Units · Derivative | 76,290 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · derivative · entry 8 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 76,290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs were granted on November 17, 2015 and February 17, 2016. The RSUs vested on June 24, 2016 and were settled on December 28, 2016. F4 · derivative.expiration_date: Each RSU represents the right to receive one ordinary share of Mylan. The RSUs were granted on November 17, 2015 and February 17, 2016. The RSUs vested on June 24, 2016 and were settled on December 28, 2016. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 46,269 | $37.50 | $1,735,087.50 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · nonDerivative · entry 6 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,279 F2 · shares: Represents withholding of ordinary shares of Mylan for the tax liability associated with the settlement of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 96,283 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · nonDerivative · entry 5 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 34,577 | $37.50 | $1,296,637.50 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · nonDerivative · entry 4 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,265 F2 · shares: Represents withholding of ordinary shares of Mylan for the tax liability associated with the settlement of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 71,951 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · nonDerivative · entry 3 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Tax withholdingOrdinary Shares | 36,662 | $37.50 | $1,374,825.00 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · nonDerivative · entry 2 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,891 F2 · shares: Represents withholding of ordinary shares of Mylan for the tax liability associated with the settlement of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 19:00 UTC | Mylan II B.V. MYL · Entity 16217 | Exercise / conversionOrdinary Shares | 76,290 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-036447 · doc4.xml · nonDerivative · entry 1 COURY ROBERT J · CIK 0001197543 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 4,957 ordinary shares of Mylan N.V. ("Mylan") previously owned indirectly through Mylan's 401(k) and Profit Sharing Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.